A Phase I/II Study Of Increasing Doses Of Epirubicin And Docetaxel Plus Pegfilgrastim For Locally Advanced Or Inflammatory Breast Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Pegfilgrastim (Primary) ; Docetaxel; Epirubicin
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Oct 2013 Planned end date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.